HLA-DQA1 (Major Histocompatibility Complex, Class II, DQ Alpha 1)

Class II alleles, especially those within DQA1 and DPB1, are important genetic factors influencing AML susceptibility in the Kazakhstani population.

To date, there have been no previous systematic reviews or meta-analyses highlighting a link between IgAV and IBD. Therefore, this systematic review is a pivotal endeavor to elucidate the complex relationship between these conditions, shaping future research in this area.

Our clustering analysis highlights distinct immune-related gene signatures in HCC, emphasising the role of antigen presentation and immune modulation in tumour progression. The findings provide a foundation for further investigation into immunotherapeutic strategies targeting key immune pathways in HCC.

Finally, analysis of the additive effects of HLA allele heterozygosity in smokers identified significant associations with several 4-digit HLA alleles, including HLA-B*08:01, HLA-A*01:01, HLA-C*07:01, HLA-DQA1*05:01, HLA-DRB1*03:01, and HLA-C*03:04. Our study provides additional evidence, with added histologic subtype information, that germline HLA-II heterozygosity is inversely associated with lung cancer risk.

P2, N=92, Recruiting, Chugai Pharmaceutical | Not yet recruiting --> Recruiting

Our findings highlight distinct associations between HLA-DQA1*05 allele subtypes and time to LoR of infliximab and adalimumab in IBD-treated patients. The protective effect of immunomodulator use is allele-specific for adalimumab. These results provide a rationale for incorporating HLA testing into personalized anti-TNF management to optimize treatment durability.

In Taiwanese IBD patients, HLA-C*03:04:01 and HLA-B*15:18:01 were significantly associated with ADA development to infliximab and adalimumab, respectively. HLA-DQA1*05 was not predictive, highlighting ethnic differences in genetic predisposition to immunogenicity.

Our findings demonstrate the feasibility of combining spatial transcriptomics with AI-driven histopathological analysis for biomarker validation. This integrative framework provides a foundation for future population-scale studies leveraging spatial omics to evaluate arsenic-associated gene signatures and assess their relevance in bladder cancer risk stratification and disease progression.

In addition, a high-risk signature score was linked to low infiltrating levels of most immune cells and a high tumor purity in the tumor microenvironment, as well as low IC50 values to several common chemotherapeutics, such as docetaxel, gefitinib, and erlotinib. Among the five prognostic genes, HLA-DQA1 harbored a relatively higher alteration frequency in LUAD (3%, alteration type: amplification). The five platelet-derived prognostic genes might be potential targets or biomarkers in lung cancer.

The HLA risk profile typical of sub-Saharan African population was observed in Ethiopians with T1D. Furthermore, they have a notably high prevalence of autoantibodies associated with T1D, CD, and AITD, which differs from earlier reports from the region but aligns with patterns observed in Caucasians.

The developed PRS showed robust predictive ability for PCa in the Taiwanese population and may inform future risk stratification and personalized interventions.

P1, N=56, Active, not recruiting, Chugai Pharmaceutical Co., Ltd | Recruiting --> Active, not recruiting